How Tumour Hypoxia Drives VEGFA Angiogenic Signalling

How Hypoxia Stabilises HIF-1α to Drive the Angiogenic Signalling Programme

Rapidly dividing tumour cells outpace their oxygen supply, creating hypoxic regions with pO2 below 2–5 mmHg. Under normoxic conditions, prolyl hydroxylase domain (PHD) enzymes hydroxylate HIF-1α at Pro402 and Pro564 — an oxygen-requiring reaction. Hydroxylated HIF-1α is recognised by the VHL E3 ubiquitin ligase complex, which ubiquitinates and rapidly degrades HIF-1α (half-life <5 minutes). Hypoxia inhibits PHD enzymes by depleting their oxygen co-substrate, preventing HIF-1α hydroxylation, blocking VHL-mediated degradation, and allowing HIF-1α to accumulate and translocate to the nucleus.

Nuclear HIF-1α dimerises with HIF-1β and binds hypoxia-response elements in genes involved in angiogenesis, glycolysis and adaptation, including VEGFA, GLUT1 and LDHA. The size and speed of induction vary by model. RAS–ERK, PI3K–AKT–mTOR, STAT3 and other signals can also modify HIF abundance or VEGFA transcription, but their effects are context-dependent rather than independent universal switches.

The VEGFR2 Signalling Cascade: From Ligand Binding to Vessel Sprouting

VEGFA165 (the dominant pro-angiogenic isoform) binds VEGFR2 (KDR) on endothelial cells with ~100 pM affinity, inducing receptor homodimerisation and autophosphorylation at multiple tyrosine residues. VEGFR2 Tyr1175 phosphorylation is the primary angiogenic signalling event, recruiting PLCγ and Shb adapter proteins to activate Ca2+/PKC (endothelial proliferation) and PI3K/AKT/mTOR (endothelial survival) downstream signalling cascades. VEGFR2-mediated SRC kinase activation phosphorylates VE-cadherin at Tyr685, loosening endothelial adherens junctions and increasing vascular permeability — the characteristic tumour vessel leakiness that drives oedema and impairs drug delivery.

Vessel sprouting is directed by DLL4/Notch lateral inhibition: high VEGFA gradients at the sprouting front activate DLL4 in leading 'tip cells', which suppresses VEGFR2 expression in adjacent 'stalk cells' through Notch signalling, creating a tip/stalk cell hierarchy that ensures directional vessel growth. ANG2 (angiopoietin-2) secreted by tip cells destabilises pericyte attachment, permitting endothelial migration into the tumour stroma. This coordinated VEGFA→VEGFR2→PI3K/AKT and VEGFA→VEGFR2→SRC/VE-cadherin signalling cascade is the molecular engine of tumour neovascularisation.

Anti-VEGF Agents: Bevacizumab, Ramucirumab, and VEGFR TKIs

Bevacizumab (Avastin) is a humanised anti-VEGFA monoclonal antibody that binds all biologically active VEGFA isoforms, preventing receptor engagement. The pivotal AVF2107 trial (Hurwitz et al., NEJM 2004) demonstrated that adding bevacizumab to irinotecan-based chemotherapy in metastatic colorectal cancer extended median OS from 15.6 to 20.3 months, securing the first anti-angiogenic approval. Bevacizumab is now approved in combination with chemotherapy or targeted agents across colorectal, NSCLC, glioblastoma, renal cell carcinoma, cervical, and hepatocellular cancers. Ramucirumab (anti-VEGFR2 antibody) blocks ligand binding at the receptor level and is approved for gastric, NSCLC, hepatocellular, and colorectal cancers.

Many VEGFR tyrosine-kinase inhibitors also inhibit PDGFR, KIT, RET, MET or other kinases, with a profile that differs by agent and concentration. Broader inhibition does not automatically mean greater efficacy and can add toxicity. Clinical use, monitoring and combination evidence must therefore be taken from disease-specific labels rather than inferred from the kinase list.

Resistance Mechanisms and Vessel Normalisation

Resistance can involve alternative angiogenic factors, pericyte support, vessel co-option, altered myeloid cells and tumour-cell adaptation. FGF, angiopoietin, PlGF and MET-associated mechanisms have been observed in selected models and diseases, but no one pathway explains every case of resistance.

Anti-VEGF treatment can create a time- and dose-dependent vascular-normalisation window in some tumours, potentially changing perfusion, immune-cell access and drug delivery. It can also reduce perfusion or select alternative vascular routes. This conditional model supports combination hypotheses but does not guarantee synergy for every anti-VEGF and immunotherapy pair.

Key Takeaways

• ·Tumour hypoxia can stabilise HIF-1α by reducing PHD-dependent hydroxylation and VHL-mediated degradation, increasing VEGFA and other adaptive programmes.
• ·The VEGFA→VEGFR2 signalling cascade activates PI3K/AKT/mTOR (endothelial survival), PLCγ/PKC (proliferation), and SRC-mediated VE-cadherin phosphorylation (vascular permeability) — the molecular drivers of tumour neovascularisation.
• ·Anti-VEGF antibodies and multi-kinase inhibitors have disease- and regimen-specific indications that should be checked in current labels.
• ·Resistance can involve alternative angiogenic factors, vessel co-option, stromal support and tumour adaptation rather than one fixed escape pathway.
• ·Vessel normalisation is a conditional, time-dependent model that can support combination strategies but does not predict benefit by itself.